KR20220125232A - Ahr 억제제 및 이의 용도 - Google Patents

Ahr 억제제 및 이의 용도 Download PDF

Info

Publication number
KR20220125232A
KR20220125232A KR1020227021773A KR20227021773A KR20220125232A KR 20220125232 A KR20220125232 A KR 20220125232A KR 1020227021773 A KR1020227021773 A KR 1020227021773A KR 20227021773 A KR20227021773 A KR 20227021773A KR 20220125232 A KR20220125232 A KR 20220125232A
Authority
KR
South Korea
Prior art keywords
cancer
compound
patient
pharmaceutically acceptable
sdi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227021773A
Other languages
English (en)
Korean (ko)
Inventor
알프레도 씨. 카스트로
3세 제임스 마틴 놀란
샤오얀 미셸 장
제이슨 세이저
Original Assignee
이케나 온콜로지, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이케나 온콜로지, 인코포레이티드 filed Critical 이케나 온콜로지, 인코포레이티드
Publication of KR20220125232A publication Critical patent/KR20220125232A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227021773A 2019-11-26 2020-11-25 Ahr 억제제 및 이의 용도 Withdrawn KR20220125232A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962940514P 2019-11-26 2019-11-26
US62/940,514 2019-11-26
US202063106530P 2020-10-28 2020-10-28
US63/106,530 2020-10-28
PCT/US2020/062116 WO2021108469A1 (en) 2019-11-26 2020-11-25 Ahr inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20220125232A true KR20220125232A (ko) 2022-09-14

Family

ID=73856333

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227021773A Withdrawn KR20220125232A (ko) 2019-11-26 2020-11-25 Ahr 억제제 및 이의 용도

Country Status (11)

Country Link
US (1) US20230026232A1 (enExample)
EP (1) EP4065090A1 (enExample)
JP (1) JP2023503167A (enExample)
KR (1) KR20220125232A (enExample)
CN (1) CN115279347A (enExample)
AU (1) AU2020391451A1 (enExample)
BR (1) BR112022010143A2 (enExample)
CA (1) CA3159315A1 (enExample)
IL (1) IL293325A (enExample)
MX (1) MX2022006312A (enExample)
WO (1) WO2021108469A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
WO2021236717A1 (en) 2020-05-20 2021-11-25 Senda Biosciences, Inc. Fused imidazole derivatives as ahr antagonists
TW202421150A (zh) * 2022-09-14 2024-06-01 美商阿克思生物科學有限公司 艾魯美冷之分散體

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103837D0 (en) * 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
EP3774767B1 (en) * 2018-04-05 2025-10-29 Beth Israel Deaconess Medical Center, Inc. Aryl hydrocarbon receptor modulators and uses thereof
KR20210151061A (ko) * 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형

Also Published As

Publication number Publication date
AU2020391451A1 (en) 2022-06-16
EP4065090A1 (en) 2022-10-05
WO2021108469A1 (en) 2021-06-03
CA3159315A1 (en) 2021-06-03
IL293325A (en) 2022-07-01
MX2022006312A (es) 2022-06-22
BR112022010143A2 (pt) 2022-08-09
JP2023503167A (ja) 2023-01-26
CN115279347A (zh) 2022-11-01
US20230026232A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP6892448B2 (ja) 悪性腫瘍の処置の方法
JP7022172B2 (ja) ２－（ｔｅｒｔ－ブチルアミノ）－４－（（１Ｒ，３Ｒ，４Ｒ）－３－ヒドロキシ－４－メチルシクロヘキシルアミノ）－ピリミジン－５－カルボキサミドの製剤
EP3153170B1 (en) Methods and uses of the quinoline derivative anlotinib in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same
US20230026232A1 (en) Ahr inhibitors and uses thereof
JP2015143278A (ja) 治療用組成物およびその使用
CN109819649B (zh) 氨基嘌呤化合物的固体形式及其使用方法
JP2018509458A (ja) ブルトン型チロシンキナーゼ阻害剤の共結晶
CN113853374B (zh) 具有增强的生物利用度的化合物形式及其制剂
JP2020533283A (ja) エンドキシフェンを製造および使用する方法
WO2018183089A1 (en) Compositions for treating and/or preventing cancer
JP2010540460A (ja) ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
CN115279345A (zh) 8-氯-n-(4-(三氟甲氧基)苯基)喹啉-2-胺的无定形固体分散体
TW201305143A (zh) 光學活性吡唑基胺基喹唑啉及其醫藥組合物及使用方法
US20210353648A1 (en) Grapiprant unit dosage forms
TWI894266B (zh) 醋酸阿比特龍和尼拉帕尼之藥物配製物
US10980765B2 (en) Isothiocyanatostilbenes as a novel method and product for treating cancer
KR20130078147A (ko) 일정한 입도를 갖는 ４，５―디아릴―３（２ｈ）―퓨라논 유도체를 포함하는 약학 조성물
KR102257685B1 (ko) Cox-2 억제제를 유효성분으로 포함하는 소염진통 예방 또는 치료용 정제 조성물
EA046804B1 (ru) Форма соединения, обладающая повышенной биодоступностью, и ее составы
BR122023016197B1 (pt) Sal cristalino de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida, composição farmacêutica o compreendendo e uso dos mesmos

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000